A case of pityriasis rubra pilaris secondary to ponatinib
Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose...
Saved in:
Main Authors: | Ariana Nateghi, Florence Lagacé-Thomassin, Julie Desrochers |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X241311341 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Refractory pityriasis rubra pilaris treated with abrocitinib
by: Filip Rob
Published: (2025-01-01) -
Pityriasis alba secondary to prolonged use of face mask
by: Gabriel Hong Zhe Wong, et al.
Published: (2024-12-01) -
Significance of Clinical-Pathological Correlation in Ponatinib Reactions
by: Judith Monserrat Corona Herrera, et al.
Published: (2025-01-01) -
False Mating of Blackbirds (Turdus merula) and Fieldfares (Turdus pilaris)
by: Dariusz Wysocki, et al.
Published: (2025-01-01) -
Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy
by: Zhuomiao Lin, et al.
Published: (2025-01-01)